Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 03, 2018 Filed May 5, 2018 00:03 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 1,922 | $52.02 | $99,982.44 |
DisclosureSEC source: 0001140361-18-021843 · doc1.xml · nonDerivative · entry 4 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2018 Filed May 5, 2018 00:03 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 1,951 | $51.25 | $99,988.75 |
DisclosureSEC source: 0001140361-18-021843 · doc1.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2018 Filed May 5, 2018 00:03 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 2,810 | $95.91 | $269,507.10 |
DisclosureSEC source: 0001140361-18-021843 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,233 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 03, 2018 Filed May 5, 2018 00:03 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 2,810 | $38.98 | $109,533.80 |
DisclosureSEC source: 0001140361-18-021843 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 01, 2018 Filed May 2, 2018 16:45 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 600 | $94.69 | $56,814.00 |
DisclosureSEC source: 0001140361-18-021149 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,261 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. F1 · price: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| April 19, 2018 Filed Apr 23, 2018 18:29 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 780 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-019228 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,233 F1 · kind: Represents performance-based restricted stock units granted on June 1, 2017. The shares were earned on April 19, 2018, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| April 19, 2018 Filed Apr 23, 2018 17:08 UTC |
Hollingshead JamesPresident, Americas
|
GrantResMed Common Stock | 1,921 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-019219 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,861 F1 · shares: Represents performance-based restricted stock units granted on February 16, 2017. The shares were earned on April 19, 2018, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 01:37 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,000 | $99.36 | $198,720.00 |
DisclosureSEC source: 0001140361-18-018865 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,072 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| April 03, 2018 Filed Apr 4, 2018 23:34 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,810 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001140361-18-017225 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,670 Underlying: ResMed Common Stock · 2,810 shares Expires 2019-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| April 03, 2018 Filed Apr 4, 2018 23:34 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 2,810 | $96.19 | $270,293.90 |
DisclosureSEC source: 0001140361-18-017225 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,453 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 03, 2018 Filed Apr 4, 2018 23:34 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 2,810 | $38.98 | $109,533.80 |
DisclosureSEC source: 0001140361-18-017225 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 01:09 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 600 | $98.19 | $58,914.00 |
DisclosureSEC source: 0001140361-18-016905 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,940 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. F1 · price: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 16:38 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,000 | $98.53 | $197,060.00 |
DisclosureSEC source: 0001140361-18-013972 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,072 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 18:30 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,810 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001140361-18-012413 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,480 Underlying: ResMed Common Stock · 2,810 shares Expires 2019-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 18:30 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 2,810 | $94.08 | $264,364.80 |
DisclosureSEC source: 0001140361-18-012413 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,453 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 18:30 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 2,810 | $38.98 | $109,533.80 |
DisclosureSEC source: 0001140361-18-012413 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 20:21 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 600 | $94.01 | $56,406.00 |
DisclosureSEC source: 0001140361-18-011568 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,540 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 18:19 UTC |
Hollingshead JamesPresident, Sleep Business
|
Tax withholdingResMed Common Stock | 862 | $93.81 | $80,864.22 |
DisclosureSEC source: 0001140361-18-009258 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,140 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 2/16/2017. Read SEC document |
| February 15, 2018 Filed Feb 17, 2018 01:27 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,000 | $93.42 | $186,840.00 |
DisclosureSEC source: 0001140361-18-008882 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,072 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| February 05, 2018 Filed Feb 6, 2018 18:14 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,810 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001140361-18-005248 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,290 Underlying: ResMed Common Stock · 2,810 shares Expires 2019-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| February 05, 2018 Filed Feb 6, 2018 18:14 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 2,810 | $96.03 | $269,844.30 |
DisclosureSEC source: 0001140361-18-005248 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,453 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 05, 2018 Filed Feb 6, 2018 18:14 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 2,810 | $38.98 | $109,533.80 |
DisclosureSEC source: 0001140361-18-005248 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 22:16 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,250 | $100.13 | $125,162.50 |
DisclosureSEC source: 0001140361-18-004816 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,072 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 18:02 UTC |
McHale RichardPresident, RC Business
|
SaleResMed Common Stock | 2,000 | $100.12 | $200,240.00 |
DisclosureSEC source: 0001140361-18-004936 · doc1.xml · nonDerivative · entry 1 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,204 F1 · price: This transaction was executed in multiple trades at prices ranging from $100.05 to $100.14. The price reported above reflects the weighted average sale price. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 18:01 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 600 | $100.11 | $60,066.00 |
DisclosureSEC source: 0001140361-18-004935 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,002 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $100.10 to $100.18. The price reported above reflects the weighted average sale price. Read SEC document |
| January 26, 2018 Filed Jan 29, 2018 17:51 UTC |
WAREHAM JOHN PDirector
|
Exercise / conversionResmed Common Stock Options · Derivative | 25,934 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001140361-18-003498 · doc1.xml · derivative · entry 4 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Commmon Stock · 25,934 shares Expires 2019-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents the date options became exercisable. Options vest in full (i) on the first Nov. 11 following the grant date or (ii) the first annual shareholders meeting following grant date. Read SEC document |
| January 26, 2018 Filed Jan 29, 2018 17:51 UTC |
WAREHAM JOHN PDirector
|
SaleResMed Common Stock | 8,300 | $102.60 | $851,580.00 |
DisclosureSEC source: 0001140361-18-003498 · doc1.xml · nonDerivative · entry 3 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 F2 · price: This transaction was executed in multiple trades at prices ranging from $102.49 to $102.73. The price reported above reflects the weighted average sale price. Read SEC document |
| January 26, 2018 Filed Jan 29, 2018 17:51 UTC |
WAREHAM JOHN PDirector
|
SaleResMed Common Stock | 17,634 | $102.09 | $1,800,255.06 |
DisclosureSEC source: 0001140361-18-003498 · doc1.xml · nonDerivative · entry 2 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,300 F1 · price: This transaction was executed in multiple trades at prices ranging from $101.49 to $102.49. The price reported above reflects the weighted average sale price. Read SEC document |
| January 26, 2018 Filed Jan 29, 2018 17:51 UTC |
WAREHAM JOHN PDirector
|
Exercise / conversionResMed Common Stock | 25,934 | $38.98 | $1,010,907.32 |
DisclosureSEC source: 0001140361-18-003498 · doc1.xml · nonDerivative · entry 1 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 17:53 UTC |
TAYLOR RONALD RDirector
|
SaleResMed Common Stock | 4,885 | $99.71 | $487,083.35 |
DisclosureSEC source: 0001140361-18-003152 · doc1.xml · nonDerivative · entry 1 TAYLOR RONALD R · CIK 0001161920 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,751 F1 · price: This transaction was executed in multiple trades at prices ranging from $99.43 to $99.90. The price reported above reflects the weighted average sale price. Read SEC document |
| January 03, 2018 Filed Jan 4, 2018 21:51 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,810 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001140361-18-000858 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,100 Underlying: ResMed Common Stock · 2,810 shares Expires 2019-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| January 03, 2018 Filed Jan 4, 2018 21:51 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 2,810 | $85.38 | $239,917.80 |
DisclosureSEC source: 0001140361-18-000858 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,453 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 03, 2018 Filed Jan 4, 2018 21:51 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 2,810 | $38.98 | $109,533.80 |
DisclosureSEC source: 0001140361-18-000858 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:55 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 600 | $84.96 | $50,976.00 |
DisclosureSEC source: 0001140361-18-000686 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,602 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $84.93 to $84.98. The price reported above reflects the weighted average sale price. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:52 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,250 | $84.99 | $106,237.50 |
DisclosureSEC source: 0001140361-18-000685 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,322 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| December 18, 2017 Filed Dec 18, 2017 21:30 UTC |
FARRELL PETER CDirector
|
GiftResMed Common Stock | 3,351 | $86.00 | $288,186.00 |
DisclosureSEC source: 0001140361-17-046520 · doc1.xml · nonDerivative · entry 4 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,896 F2 · kind: Represents a gift of shares to the Greater Houston Community Foundation. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F4 · price: The price reported above represents the average of the high and low trading price on the day of the transaction. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 21:30 UTC |
FARRELL PETER CDirector
|
GiftResMed Common Stock | 1,180 | $84.97 | $100,264.60 |
DisclosureSEC source: 0001140361-17-046520 · doc1.xml · nonDerivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,427 F3 · kind: Represents a gift of shares to Project Veritas. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F4 · price: The price reported above represents the average of the high and low trading price on the day of the transaction. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 21:30 UTC |
FARRELL PETER CDirector
|
GiftResMed Common Stock | 23,689 | $84.43 | $2,000,062.27 |
DisclosureSEC source: 0001140361-17-046520 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,607 F2 · kind: Represents a gift of shares to the Greater Houston Community Foundation. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F4 · price: The price reported above represents the average of the high and low trading price on the day of the transaction. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 21:30 UTC |
FARRELL PETER CDirector
|
GiftResMed Common Stock | 23,689 | $84.43 | $2,000,062.27 |
DisclosureSEC source: 0001140361-17-046520 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,296 F1 · kind: Represents a gift of shares to the Farrell Family Foundation. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F4 · price: The price reported above represents the average of the high and low trading price on the day of the transaction. Read SEC document |
| December 05, 2017 Filed Dec 6, 2017 17:31 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GiftResMed Common Stock | 1,184 | $84.46 | $100,000.64 |
DisclosureSEC source: 0001140361-17-045162 · doc1.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 110,063 F1 · shares: Represents a gift of shares to the Douglas Family Fund-Giving charitable account. Mr. Douglas has no beneficial interest, control or dispositive power over the gifted shares. F2 · price: The price reported above represents the average of the high and low trading price on the day of the transaction. F3 · balance_after: Includes transfer of 19,879 shares between the direct holdings and the Douglas Family Trust indirect holdings on 11/29/2017. Read SEC document |
| December 04, 2017 Filed Dec 5, 2017 21:29 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,804 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001140361-17-045061 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,910 Underlying: ResMed Common Stock · 2,804 shares Expires 2019-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| December 04, 2017 Filed Dec 5, 2017 21:29 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 2,804 | $84.17 | $236,012.68 |
DisclosureSEC source: 0001140361-17-045061 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,453 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 04, 2017 Filed Dec 5, 2017 21:29 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 2,804 | $38.98 | $109,299.92 |
DisclosureSEC source: 0001140361-17-045061 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:37 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,250 | $85.36 | $106,700.00 |
DisclosureSEC source: 0001140361-17-044862 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,572 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:16 UTC |
FARRELL PETER CDirector
|
GiftResMed Common Stock | 2,948 | $84.80 | $249,990.40 |
DisclosureSEC source: 0001140361-17-044227 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,985 F1 · kind: Represents a gift of shares to Donors Trust, Inc. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F2 · price: The price reported above represents the average of the high and low trading price on the day of the transaction. Read SEC document |
| November 27, 2017 Filed Nov 29, 2017 01:44 UTC |
Hollingshead JamesPresident, Americas
|
Tax withholdingResMed Common Stock | 4,161 | $84.63 | $352,145.43 |
DisclosureSEC source: 0001140361-17-044037 · doc1.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,202 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014. Read SEC document |
| November 27, 2017 Filed Nov 29, 2017 01:44 UTC |
Hollingshead JamesPresident, Americas
|
GrantResMed Common Stock | 7,973 | $84.63 | $674,754.99 |
DisclosureSEC source: 0001140361-17-044037 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,363 F1 · kind: Shares acquired on vesting of performance-based restricted stock units. The PSUs were granted November 19, 2014, with a three-year performance period. The shares were earned and vested November 27, 2017, when the ResMed compensation committee certified performance. F2 · shares: Shares earned based on performance at 57% of the target award. Read SEC document |
| November 27, 2017 Filed Nov 28, 2017 23:33 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 4,001 | $84.63 | $338,604.63 |
DisclosureSEC source: 0001140361-17-044019 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,453 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014. Read SEC document |
| November 27, 2017 Filed Nov 28, 2017 23:33 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 7,666 | $84.63 | $648,773.58 |
DisclosureSEC source: 0001140361-17-044019 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,454 F1 · kind: Shares acquired on vesting of performance-based restricted stock units. The PSUs were granted November 19, 2014, with a three-year performance period. The shares were earned and vested November 27, 2017, when the ResMed compensation committee certified performance. F2 · shares: Shares earned based on performance at 57% of the target award. Read SEC document |
| November 27, 2017 Filed Nov 28, 2017 23:30 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 8,920 | $84.63 | $754,899.60 |
DisclosureSEC source: 0001140361-17-044018 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,822 F1 · kind: Shares acquired on vesting of performance-based restricted stock units. The PSUs were granted November 19, 2014, with a three-year performance period. The shares were earned and vested November 27, 2017, when the ResMed compensation committee certified performance. F2 · shares: Shares earned based on performance at 57% of the target award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.